NCT00387140
Completed
Phase 2
A Randomized Double-blind, Placebo-and Active Comparator-Controlled 2-Part Study to Evaluate the Efficacy of MK2295 in Patients With Postoperative Dental Pain
DrugsMK2295
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Pain, Postoperative
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 89
- Primary Endpoint
- Peak analgesic response, safety, and tolerability
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study is being conducted to evaluate the safety and tolerability of the drug and to evaluate its efficacy compared to placebo and to ibuprofen in the treatment of postoperative dental pain in male patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients in generally good health who are scheduled to have two or more third molars removed, at least one of which is partially or completely embedded in bone and is a mandibular impaction
Exclusion Criteria
- •Patient has a temperature of 37.5C or greater prior to dosing
- •Patient has participated in another clinical study within the last 4 weeks
Outcomes
Primary Outcomes
Peak analgesic response, safety, and tolerability
Time Frame: Over 24 Hours
Secondary Outcomes
- Onset of analgesia, duration of analgesia(Over 24 Hours)
Similar Trials
Completed
Phase 1
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy VolunteersHealthyNCT00941018Resolvyx Pharmaceuticals, Inc56
Completed
Phase 1
An Evaluation of VR942 in Healthy Volunteers and Patients With Mild AsthmaAsthmaNCT02473939Vectura Limited85
Unknown
Phase 1
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult SubjectsHealthyNCT02622230Xinjiang Uygur Pharmaceutical Co., Ltd.60
Completed
Phase 1
A Study to Evaluate LY3202328 in Overweight Healthy Participants and DyslipidemiaDyslipidemiasNCT02714569Eli Lilly and Company60
Terminated
Phase 1
Multiple Ascending Dose Study in Subjects With Type 2 DiabetesDiabetes MellitusNCT01856881Amgen86